Spectral Medical Inc T.EDT

The time arrived 15 years ago, but the "rewards" just now?

[SouthernTierTom]

 

Comment

 

Crit Care

 

•  
•  
•  

. 2007;11(3):137.

 doi: 10.1186/cc5918.

A targeted extracorporeal therapy for endotoxemia: the time has come

 

John A Kellum 1

Affiliations expand

• PMID: 17567925
•  
• PMCID: PMC2206410
•  
• DOI: 10.1186/cc5918

Free PMC article

Abstract

 

Endotoxemia, whether primary (due to Gram-negative infection) or secondary (due to epithelial barrier dysfunction), appears to be extremely common in the critically ill and injured. High levels of endotoxin activity are associated with worse clinical outcomes. In Japan, polymyxin B hemoperfusion has been available to treat endotoxemia for more than ten years. Multiple small trials, often limited by methodological quality, show that polymyxin B hemo-perfusion may have favorable effects on survival and hemodynamics. Further study of this therapy would seem justified.

[mercedesman]

Good reminder & post. It's like a "back-end loaded" fund I guess...and the ones that were brung are feeling it. MM

[Domino55]

I'm not sure Toray would forgo 125 plus billion in cumulative global revenue, treatment exposure and patent establishment so some execs at a pee on Canadian biotech can enrich themselves through 15 years of delay to sell for $8.00 a share, but Ok it makes perfect business sense. I'm assuming that was a response to Alex Jones....

[SouthernTierTom]

A LOT of tributaries have formed on the back of the le$$ than raging rivers that have formed on the banks of the smallest Great lake buy size, but 2nd smallest buy volume..... Hard to imagine how CTSO got to $15.24 USD with ALL those German salesforce issues, or how Aethlon and Sigy have pushed ahead... 2007, was 15 years AGO..Bear in MIND, twas August 22 2014 when the FDA said NO more Spectral